Ransohoff RM - Search Results

1

Multiple sclerosis normal-appearing white matter: pathology-imaging correlations.

Moll NM, Rietsch AM, Thomas S, Ransohoff AJ, Lee JC, Fox R, Chang A, Ransohoff RM, Fisher E. Moll NM, et al. Among authors: ransohoff aj, ransohoff rm. Ann Neurol. 2011 Nov;70(5):764-73. doi: 10.1002/ana.22521. Ann Neurol. 2011. PMID: 22162059 Free PMC article.

2

Defining interferon beta response status in multiple sclerosis patients.

Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Rudick RA, et al. Among authors: ransohoff rm. Ann Neurol. 2004 Oct;56(4):548-55. doi: 10.1002/ana.20224. Ann Neurol. 2004. PMID: 15389896 Clinical Trial.

3

Cortical demyelination in PML and MS: Similarities and differences.

Moll NM, Rietsch AM, Ransohoff AJ, Cossoy MB, Huang D, Eichler FS, Trapp BD, Ransohoff RM. Moll NM, et al. Among authors: ransohoff aj, ransohoff rm. Neurology. 2008 Jan 29;70(5):336-43. doi: 10.1212/01.WNL.0000284601.54436.e4. Neurology. 2008. PMID: 17914063

4

Imaging correlates of leukocyte accumulation and CXCR4/CXCL12 in multiple sclerosis.

Moll NM, Cossoy MB, Fisher E, Staugaitis SM, Tucky BH, Rietsch AM, Chang A, Fox RJ, Trapp BD, Ransohoff RM. Moll NM, et al. Among authors: ransohoff rm. Arch Neurol. 2009 Jan;66(1):44-53. doi: 10.1001/archneurol.2008.512. Arch Neurol. 2009. PMID: 19139298 Free PMC article.

5

Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis.

Mahad D, Callahan MK, Williams KA, Ubogu EE, Kivisäkk P, Tucky B, Kidd G, Kingsbury GA, Chang A, Fox RJ, Mack M, Sniderman MB, Ravid R, Staugaitis SM, Stins MF, Ransohoff RM. Mahad D, et al. Among authors: ransohoff rm. Brain. 2006 Jan;129(Pt 1):212-23. doi: 10.1093/brain/awh655. Epub 2005 Oct 17. Brain. 2006. PMID: 16230319

6

VCAM-1-positive microglia target oligodendrocytes at the border of multiple sclerosis lesions.

Peterson JW, Bö L, Mörk S, Chang A, Ransohoff RM, Trapp BD. Peterson JW, et al. Among authors: ransohoff rm. J Neuropathol Exp Neurol. 2002 Jun;61(6):539-46. doi: 10.1093/jnen/61.6.539. J Neuropathol Exp Neurol. 2002. PMID: 12071637

7

New directions in MS therapeutics: vehicles of hope.

Fox RJ, Ransohoff RM. Fox RJ, et al. Among authors: ransohoff rm. Trends Immunol. 2004 Dec;25(12):632-6. doi: 10.1016/j.it.2004.09.012. Trends Immunol. 2004. PMID: 15530830 Review.

8

Chemokine receptors as biomarkers in multiple sclerosis.

Fox RJ, Kivisäkk P, Lee JC, Tucky B, Lucchinetti C, Rudick RA, Ransohoff RM. Fox RJ, et al. Among authors: ransohoff rm. Dis Markers. 2006;22(4):227-33. doi: 10.1155/2006/694283. Dis Markers. 2006. PMID: 17124344 Free PMC article.

9

Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy?

Eichler FS, Ren JQ, Cossoy M, Rietsch AM, Nagpal S, Moser AB, Frosch MP, Ransohoff RM. Eichler FS, et al. Among authors: ransohoff rm. Ann Neurol. 2008 Jun;63(6):729-42. doi: 10.1002/ana.21391. Ann Neurol. 2008. PMID: 18571777

10

Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis.

Rudick RA, Rani MR, Xu Y, Lee JC, Na J, Shrock J, Josyula A, Fisher E, Ransohoff RM. Rudick RA, et al. Among authors: ransohoff rm. PLoS One. 2011;6(5):e19262. doi: 10.1371/journal.pone.0019262. Epub 2011 May 13. PLoS One. 2011. PMID: 21602934 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

455 results

Search Page

Filters